There is an increase in tuberculosis and mycobacterial disease caused by nontuberculous mycobacteria. Infections by more than one mycobacterial species in immunosuppressed patients are increasingly being reported. The rapid diagnosis of mycobacterial disease relies primarily on the detection of acidfast bacteria by direct microscopy. The infecting mycobacterial species can usually be identified only after culture of the organism, a time-consuming procedure. However, some mycobacteria, e.g., Mycobacterium genavense and M. ulcerans, are difficult to grow and some, e.g., M. leprae, cannot be cultured in vitro. Since the choice of therapy is dependent on the infecting species (1, 15) , identification of the organism(s) at an early phase of disease is required for optimal therapy and medical care decisions, e.g., whether isolation of the patient is necessary. The practice of many clinicians has been to initiate treatment for M. tuberculosis upon microscopic detection of mycobacteria in specimens, often several weeks before species identification (12) . We developed a PCR assay based on DNA coding for the 16S subunit of rRNA (16S rDNA) (11) . We combined this with our IS6110-based PCR assay for detection of M. tuberculosis (9) in a "multiplex" PCR assay. The PCR product is analyzed in a reverse cross-blot hybridization assay with 13 species-specific probes and a Mycobacterium-specific probe. This approach enables detection of infection by a single mycobacterial species or simultaneous infections by more than one species. The objective of this study was to demonstrate the clinical usefulness of the multiplex PCR assay. We used the assay to identify the infecting organism(s) directly in specimens taken from patients.
MATERIALS AND METHODS
Clinicians sent us samples from patients for whom difficulties with diagnosis were experienced or could be anticipated, e.g., patients with granulomatous disease, patients with suspected extrapulmonary paucibacillary tuberculosis, immunocompromised patients (human immunodeficiency virus [HIV]-positive or AIDS patients), immigrants and refugees from countries where tuberculosis is endemic, and patients in whom mycobacterial infection other than by M. tuberculosis was suspected.
Two hundred fifty-nine clinical specimens, consisting of samples of sputum (n ϭ 31), tissue obtained by biopsy (n ϭ 87), lymph node obtained by biopsy (n ϭ 37), feces (n ϭ 7), urine (n ϭ 6), blood (n ϭ 10), cerebrospinal fluid (CSF) (n ϭ 36), ascitic fluid (n ϭ 6), pleural fluid (n ϭ 15), pericardial fluid (n ϭ 3), bronchoalveolar lavage fluid (n ϭ 20), and gastric lavage fluid (n ϭ 1), were obtained from 177 patients who had clinical symptoms compatible with mycobacterial disease. The specimens, which were obtained from various university and teaching hospitals in The Netherlands, were taken before therapy was started. They were divided into two portions, one for conventional mycobacterium detection methods (microscopy and culture) and one for PCR.
Microscopy and culture were performed according to standard methods (6) at the microbiology laboratories of the hospitals to which the patients were referred. Strains were identified by standard methods (6); identifying features included physical characteristics, pigmentation, growth at 25°C, niacin test results, para-nitrobenzoic acid test results, and AccuProbe (Gen-probe, San Diego, Calif.) hybridization assay results. The PCR assays were performed at the Royal Tropical Institute, and results were reported to the clinicians within 3 days.
DNA isolation from the clinical specimens was performed as previously described (10) . For the amplification of mycobacterial 16S rDNA sequences, we used the 5Ј-biotinylated primers pMyc14bio (5Ј-GRGRTACTCGAGTGGCGA AC-3Ј) (R ϭ A or G) and pMyc7bio (5Ј-GGCCGGCTACCCGTCGTC-3Ј). Primer Pt18 (5Ј-GAACCGTGAGGGCATCGAGG-3Ј) and the 5Ј-biotinylated primer INS2bio (5Ј-GCGTAGGCGTCGGTGACAAA-3Ј), amplifying the M. tuberculosis complex-specific insertion sequence IS6110, were included in the PCR mixture. PCR and analysis of the PCR products by reverse cross-blot hybridization were performed as previously described, including the use of DNA glycosylase in combination with dUTP instead of dTTP to break down possible contamination with amplicons and the use of modified M. smegmatis 1008 as an internal control for inhibition (8, 11) . Briefly, samples of the PCR products were denatured and allowed to hybridize with the specific probes, which were attached to a reinforced nitrocellulose membrane. The assay was performed in a cross format with a cross-blotter (Accutran-Cross ACC 100/0; Schleicher & Schuell, Dassel, Germany), permitting hybridization of the biotinylated DNA strands from one PCR product with all probes simultaneously. The hybridized PCR products on the membrane were detected by incubation with a streptavidin-alkaline phosphatase conjugate and a color substrate (4-nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolylphosphate). Probe Pt3 (5Ј-GAACGG CTGATGACCAAACT-3Ј) was used to capture the IS6110 PCR product of M. tuberculosis, and pTub1 (5Ј-ACCACAAGACATGCATCCCG-3Ј) was used to capture the 16S rDNA PCR product of M. tuberculosis. The 16S rDNA PCR products of the following species were captured by the indicated probes: M. avium, pAvi7 (5Ј-CCAGAAGACATGCGTCTTGAG-3Ј); M. intracellulare, pInt5 (5Ј-C ACCTAAAGACATGCGCCTAA) and pInt7 (5Ј-CACCAAAAGACATGCGT CTAA-3Ј); M. kansasii complex and M. scrofulaceum complex, pKan7 (5Ј-CAA GGCATGCGCCAAGTGGT-3Ј); M. xenopi, pXen1 (5Ј-ACCACCCCACATGC GCAGAA-3Ј); M. fortuitum and M. senegalense, pFor1 (5Ј-ACCACACACCAT GAAGCGCG-3Ј); M. chelonae, pChe3 (5Ј-CCACTCACCATGAAGTGTGTG -3Ј); M. genavense, pGen1 5Ј-CCACAAAACATGCGTTCCGTG-3Ј); M. gordonae, pGor5 (5Ј-TGTGTCCTGTGGTCCTATTCG-3Ј); M. marinum and M. ulcerans, pMar2 (5Ј-CGGGATTCATGTCCTGTGGT-3Ј); M. leprae, pLep1 (5Ј-A CCACAAGACATGCGCCTTG-3Ј); and M. smegmatis, pSme3 (5Ј-CATGCGA CCAGCAGGGTGTA-3Ј). pMyc5a (5Ј-GGGCCCATCCCACACCGC-3Ј), a general probe for mycobacteria, was also used. The nucleotide sequences of primers pMyc14bio, pMyc7bio, Pt18, and INS2bio and probes Pt3, pTub1, pInt5, pInt7, pXen1, pFor1, and pMyc5a were published previously (9, 11, 13) . Figure 1 shows the results of the PCR assay of 17 representative specimens. Using the multiplex PCR assay we were able to identify mycobacterial species within 48 h. Table 1 shows the PCR and culture results for the 65 microscopy-positive samples. Culture and PCR results were in agreement in most cases. For most of the specimens for which the PCR result was positive but no organism was cultured, the mycobacteria were fastidious (M. genavense) or noncultivable (M. leprae). There were no false-positive PCR results or microscopy artifacts, and all the microscopy-positive specimens had a positive result by PCR and/or culture. Table 2 shows the PCR and culture results for the 194 microscopy-negative samples. Most specimens were both PCR and culture negative. A low number of specimens were found to contain the same organisms by PCR and culture. In the majority of patients from whom these specimens were obtained, illness was caused by M. tuberculosis. There were discrepancies in the results for other specimens. These results are discussed in detail below. Table 3 shows the results of the multiplex PCR assay, microscopy, and culture for 116 specimens from the 64 patients for whom at least one test gave a positive result. Two patients (patients 6 and 17) had double infections with different mycobacterial species. The PCR assay of specimens from patient 6 identified M. tuberculosis and M. avium in biopsy samples from the spleen and a vertebral body but only M. avium in two separate blood samples. Culturing of these four samples yielded only M. avium, identified biochemically, by the AccuProbe system, and by our multiplex PCR assay. M. avium grows more rapidly than M. tuberculosis and so may have obscured M. tuberculosis in culture. In the vertebral biopsy sample, in addition to the 16S rDNA target of M. avium found by PCR, we identified the IS6110 target (identifiable with Pt3) of M. tuberculosis but failed to detect the 16S rDNA target (identifiable with pTub1) of M. tuberculosis. In PCR with genus-specific probes, if more than one mycobacterial species is present in the specimen, there will be competition for primers between the two 16S rDNA targets. When one of the targets is present at an excess of at least 100-fold, only that target will be detected (8) . However, with our multiplex PCR M. tuberculosis cannot be missed, even in the presence of a large excess of other myco- e Clinical evidence of tuberculosis, but patient was not treated because of his poor condition; he died a few weeks later. f Patient was treated for tuberculosis; his father had had microscopy-positive pulmonary tuberculosis previously. g Patient had had tuberculosis 1 year previously and was noncompliant.
RESULTS AND DISCUSSION
medium (3) . We postulated that our PCR did not detect M. avium in the feces of patient 17 because of an excess of M. genavense bacteria, resulting in competition that masked the presence of M. avium. This hypothesis was investigated by performing PCR on the fecal samples with a primer set amplifying the multicopy target IS1245, which is specific for M. avium (5) . This M. avium-specific PCR was positive, indicating that competition was the cause of the negative results in the original multiplex PCR assay. In the future we will add this third, IS1245-specific primer set to the PCR mixture to avoid missing M. avium as a result of competition with other nontuberculous mycobacteria. The ability to identify M. genavense is important; it has been suggested that the prevalence of M. genavense infection in HIV-seropositive patients is underestimated (7). We identified 21 M. genavense strains by PCR, but only 3 strains were isolated by culture. M. tuberculosis complex mycobacteria were detected in 36 specimens; nontuberculous mycobacteria were found in 66 (64.7%) specimens (Tables 1 and 2 ). Nontuberculous mycobacteria were identified in 49 (75.4%) of the 65 microscopypositive specimens; nontuberculous mycobacteria were detected in 48 (98%) specimens by PCR and in only 32 (65%) specimens by culture ( Table 1) . One of the advantages of the multiplex PCR is evident here, since in these cases we were able to exclude tuberculosis and identify the infecting species. This meant that appropriate therapy could be given and isolation of microscopy-positive patients could be stopped, since opportunistic mycobacteria are normally not transmissible (15) . The practice of many clinicians has been to initiate treatment for M. tuberculosis upon microscopic detection of mycobacteria in specimens, often several weeks before species identification (11) . With the multiplex PCR, overtreatment can be reduced. Mycobacteria were identified by PCR and/or culture in 37 of 194 microscopy-negative specimens. In 17 (45.9%) of these specimens, nontuberculous mycobacteria were detected (Table 2) .
Mycobacterial infections caused by the M. avium complex (M. avium and M. intracellulare) (MAC) were relatively frequent, occurring in 21 of the patients studied. There is a high rate of treatment failure in disseminated MAC disease because of delayed diagnosis (2, 4). The PCR test described here could be very helpful in improving treatment, since effective therapy depends on early and correct diagnosis.
PCR is particularly useful in cases in which mycobacteria cannot be cultured in vitro. It is the only test available which can rapidly confirm a clinical diagnosis of leprosy. The diagnosis of leprosy can be particularly difficult to make in areas in which the disease is not endemic, where doctors are not familiar with it. For patients 18 and 19, M. leprae was identified by PCR. Patient 18 had a persistent skin wound thought on the basis of clinical observations to be caused by either an M. leprae or an M. ulcerans infection. The final diagnosis was borderline lepromatous leprosy, as the clinical findings and the response to antileprosy treatment were in accord with the PCR result. Patient 19 had a persistent cough and a microscopy-positive sputum sample and had had previous contact with a patient with M. leprae infection. The clinician was uncertain whether M. tuberculosis or M. leprae was the causative organism, since pulmonary infection with M. leprae is uncommon. A presumptive diagnosis of tuberculosis was made. An expert opinion from a specialist in leprosy stated that the clinical evidence was compatible with leprosy, and the patient responded to antileprosy therapy.
For 44 specimens there was a discrepancy between the results obtained by culture and those obtained by PCR (Tables 1  and 2 ). None of the patients received therapy before samples were taken. There were 21 microscopy-positive, PCR-positive, culture-negative specimens (from patients 4 Table  3) . A second specimen from patient 24 gave a culture result in accord with the PCR result. We concluded that the PCR results for the specimens from this patient represent true-positive test results. The cultures for patients 4 and 5 were repeatedly negative, indicating that the mycobacteria detected by microscopy and identified by multiplex PCR were not viable. These two patients had clinically active tuberculosis, according to class 3 of the diagnostic standards of the American Thoracic Society (1), and responded to antituberculous treatment. Patients 18 and 19 were discussed above. Patients 16, 25, 26, and 29 were AIDS patients; patient 33 was severely immunodeficient. For all these patients, the clinical findings and the granulomatous tissue biopsy samples were in accord with the microscopy and PCR results. Therefore, we regard the PCR results for these patients as true positive.
There were two false-negative PCR results for specimens (from patients 34 and 62) for which culture was positive and PCR was negative (Table 3 ) (one was microscopy positive [ Table 1 ], and one was microscopy negative [ Table 2 ]). M. xenopi was identified by culture in the microscopy-positive bronchoalveolar lavage fluid from patient 34 (Table 3) ; PCR gave the only positive test result with sputum from the same patient, with the probe for M. xenopi. M. marinum was cultured from a microscopy-negative skin biopsy sample from patient 62. In both cases sampling error is the most likely explanation for the failure of PCR. For 21 specimens, PCR was positive but microscopy and culture were negative (Table 2) . There were six patients (patients 15, 34, 41, 45, 50, and 59) for whom other specimens were culture positive for the species identified by PCR, so we regard the positive PCR as a true-positive result. The positive PCR results for 10 of these 21 specimens were compatible with the clinical evidence in those patients (from patients 46, 51 [two specimens], 53, 54, 55 [four specimens], and 56) (Table 3) , so we regard the PCR results as being correct. For five specimens (from patients 47 to 49, 52, and 58), PCR was positive but culture, microscopy, and, importantly, clinical evidence were not in accord with the PCR results ( Table 3 ). For patient 47 the final diagnosis was aspergillosis; for patient 48, all cultures remained negative and the final diagnosis is pleurisy of unknown origin; for patient 49, who came recently from Suriname, the final diagnosis was viral infection; patient 52 had non-Hodgkin's lymphoma; and patient 58 had a cutaneous streptococcal infection. We regard the PCR results for these specimens as false positive (Table 4) .
Taking discrepancies, i.e., specimens which we regard as true positive, into consideration, sensitivity and specificity were calculated and are shown in Table 4 . For PCR, the overall sensitivity was 97.9%, the specificity was 96.9%, the positive predictive value was 95.0%, and the negative predictive value was 98.7%. For culture, these values were 60.8, 100, 100, and 81.0%, respectively.
We advise that PCR-based identification be performed on all microscopy-positive specimens when clinical evidence suggests that mycobacteria other than M. tuberculosis may be involved. For such specimens, the sensitivity, specificity, and both positive and negative predictive values of this PCR are close to or equal to 100%. This new PCR assay identifies M. tuberculosis and the most important opportunistic mycobacteria. Direct identification in clinical specimens is possible, and results are available within 48 h. Mycobacteria that are difficult to culture and are therefore frequently missed, e.g., M. genavense and M. ulcerans, are easily identified in this PCR assay. Our multiplex PCR is also a tool for investigating the prevalence of multiple infections. Identification of mycobacteria at an early stage of disease can be helpful in the care of patients, enabling the optimal therapy to be given and preventing unnecessary and expensive isolation. The data that we provide here will enable those interested to carry out the test themselves and evaluate it in the context of their own patient populations.
